Log in
E-mail
Password
Remember
Forgot password ?
Become a member for free
Sign up
Sign up
Settings
Settings
Dynamic quotes 
OFFON

4-Traders Homepage  >  Equities  >  Nasdaq  >  Gilead Sciences    GILD

SummaryQuotesChartsNewsAnalysisCalendarCompanyFinancialsConsensusRevisions 
News SummaryMost relevantAll newsSector newsTweets

Gilead Sciences, Inc. : U.S. FDA Grants Priority Review for Truvada? for Reducing the Risk of Acquiring HIV Infection

share with twitter share with LinkedIn share with facebook
share via e-mail
0
02/14/2012 | 01:38am CET

FOSTER CITY, Calif.--(BUSINESS WIRE)--Feb. 13, 2012-- Gilead Sciences, Inc. (Nasdaq:GILD) announced today that the U.S. Food and Drug Administration (FDA) has accepted the supplemental New Drug Application (sNDA) and granted a six-month Priority Review for once-daily Truvada® (emtricitabine/tenofovir disoproxil fumarate) for pre-exposure prophylaxis (PrEP) to reduce the risk of HIV-1 infection among uninfected adults. Truvada was approved by the FDA in 2004 for the treatment of HIV-1 infection and is currently the most-prescribed antiretroviral treatment in the United States.

The FDA grants priority review status to drug candidates that provide major advances in treatment or provide a treatment where no adequate therapy exists. Gilead submitted the Truvada for PrEP sNDA on December 15, 2011. The FDA has set a target review date for Truvada for PrEP under the Prescription Drug User Fee Act (PDUFA) of June 15, 2012. The agency has also indicated that Truvada for PrEP will be discussed at the FDA Antiviral Drugs Advisory Committee meeting scheduled in May.

If the sNDA is approved, Truvada would be the first agent indicated for uninfected individuals to reduce the risk of acquiring HIV. The sNDA is based on the results of two large placebo-controlled trials of Truvada as PrEP sponsored by the U.S. National Institutes of Health and the University of Washington. Several other clinical studies support the use of Truvada for HIV risk reduction.

Truvada is not currently indicated to reduce the risk of HIV infection.

About Gilead Sciences

Gilead Sciences is a biopharmaceutical company that discovers, develops and commercializes innovative therapeutics in areas of unmet medical need. The company's mission is to advance the care of patients suffering from life-threatening diseases worldwide. Headquartered in Foster City, California, Gilead has operations in North America, Europe and Asia Pacific.

Forward-Looking Statement

This press release includes forward-looking statements, within the meaning of the Private Securities Litigation Reform Act of 1995, that are subject to risks, uncertainties and other factors, including the risk that the FDA may not approve Truvada for HIV-1 risk reduction, and any approval, if granted, may have significant limitations on its use. Additionally, even if approved, physicians may be reluctant to prescribe the product for HIV risk reduction, and payers may be reluctant to approve or provide reimbursement for the product for HIV risk reduction. As a result, there may not be significant use of Truvada as a risk reduction tool. These risks, uncertainties and other factors could cause actual results to differ materially from those referred to in the forward-looking statements. The reader is cautioned not to rely on these forward-looking statements. These and other risks are described in detail in Gilead's Quarterly Report on Form 10-Q for the quarter ended September 30, 2011, as filed with the U.S. Securities and Exchange Commission. All forward-looking statements are based on information currently available to Gilead, and Gilead assumes no obligation to update any such forward-looking statements.

U.S. . www.Truvada.com

Truvada is a registered trademark of Gilead Sciences, Inc.

For more information on Gilead Sciences, please visit the company's website at or call Gilead Public Affairs at 1-800-GILEAD-5 or 1-650-574-3000.

Source: Gilead Sciences, Inc.

Gilead Sciences, Inc.
Patrick O'Brien, 650-522-1936 (Investors)
Cara Miller, 650-522-1616 (Media)

share with twitter share with LinkedIn share with facebook
share via e-mail
0
Latest news on GILEAD SCIENCES
11/21 GILEAD SCIENCES' : Trademark Application for "JOTAVO" Filed
11/21 GILEAD SCIENCES : Recent Findings in Antiretrovirals Described by Researchers fr..
11/21 GILEAD SCIENCES : An Application for the Trademark "FINFEXTI" Has Been Filed by ..
11/21 GILEAD SCIENCES : An Application for the Trademark "OMAGNEO" Has Been Filed by G..
11/21 GILEAD SCIENCES : Trademark Application for "YOTRUGO" Filed by Gilead Sciences
11/21 GILEAD SCIENCES' : Trademark Application for "ZEXLIF" Filed
11/21 GILEAD SCIENCES : An Application for the Trademark "TALREDY" Has Been Filed by G..
11/21 GILEAD SCIENCES : New Findings in Antiretrovirals Described from Gilead Sciences..
11/20 SPRING BANK PHARMACEUTICALS : Announces Positive Top-Line Results from the Secon..
11/15 GILEAD SCIENCES : Today’s Research Reports on Trending Tickers: Gilead Sciences ..
More news
News from SeekingAlpha
11/21 Juno Clinical Trial Updates Continue To Impress
11/21 Tracking Ole Andreas Halvorsen's Viking Global Portfolio - Q3 2017 Update
11/21 Ultragenyx Reaches The Finish Line For Rare Disease
11/20 DIVGRO PULSE : November 2017
11/20 Cytodyn Is Worth A Look Before Phase 3 HIV Data
Financials ($)
Sales 2017 25 806 M
EBIT 2017 15 765 M
Net income 2017 10 588 M
Debt 2017 12 742 M
Yield 2017 2,93%
P/E ratio 2017 9,21
P/E ratio 2018 11,70
EV / Sales 2017 4,14x
EV / Sales 2018 4,69x
Capitalization 94 196 M
Chart GILEAD SCIENCES
Duration : Period :
Gilead Sciences Technical Analysis Chart | GILD | US3755581036 | 4-Traders
Technical analysis trends GILEAD SCIENCES
Short TermMid-TermLong Term
TrendsBearishNeutralNeutral
Income Statement Evolution
Consensus
Sell
Buy
Mean consensus OUTPERFORM
Number of Analysts 28
Average target price 84,9 $
Spread / Average Target 18%
EPS Revisions
Managers
NameTitle
John F. Milligan President, Chief Executive Officer & Director
John C. Martin Executive Chairman
Kevin B. Young Chief Operating Officer
Robin L. Washington Chief Financial Officer & Executive Vice President
Norbert W. Bischofberger Chief Scientific Officer & Executive VP-Research
Sector and Competitors
1st jan.Capitalization (M$)
GILEAD SCIENCES1.16%94 196
REGENERON PHARMACEUTICALS6.67%41 388
VERTEX PHARMACEUTICALS100.10%36 580
GENMAB4.43%11 537
EXELIXIS, INC.76.93%7 589
BLUEBIRD BIO INC164.51%7 580